- Home
- SRM vs CANF Comparison
SRM vs CANF Comparison
Compare SRM & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRM
- CANF
- Stock Information
- Founded
- SRM 1979
- CANF 1994
- Country
- SRM United States
- CANF Israel
- Employees
- SRM N/A
- CANF N/A
- Industry
- SRM
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- SRM
- CANF Health Care
- Exchange
- SRM Nasdaq
- CANF Nasdaq
- Market Cap
- SRM 9.0M
- CANF 7.9M
- IPO Year
- SRM 2023
- CANF N/A
- Fundamental
- Price
- SRM $0.43
- CANF $1.18
- Analyst Decision
- SRM
- CANF Strong Buy
- Analyst Count
- SRM 0
- CANF 2
- Target Price
- SRM N/A
- CANF $14.00
- AVG Volume (30 Days)
- SRM 278.8K
- CANF 408.4K
- Earning Date
- SRM 05-09-2025
- CANF 05-06-2025
- Dividend Yield
- SRM N/A
- CANF N/A
- EPS Growth
- SRM N/A
- CANF N/A
- EPS
- SRM N/A
- CANF N/A
- Revenue
- SRM $4,311,382.00
- CANF $674,000.00
- Revenue This Year
- SRM N/A
- CANF $461.72
- Revenue Next Year
- SRM N/A
- CANF N/A
- P/E Ratio
- SRM N/A
- CANF N/A
- Revenue Growth
- SRM N/A
- CANF N/A
- 52 Week Low
- SRM $0.26
- CANF $1.22
- 52 Week High
- SRM $1.66
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- SRM 61.26
- CANF 37.60
- Support Level
- SRM $0.28
- CANF $1.14
- Resistance Level
- SRM $0.38
- CANF $1.27
- Average True Range (ATR)
- SRM 0.06
- CANF 0.12
- MACD
- SRM 0.01
- CANF -0.02
- Stochastic Oscillator
- SRM 76.45
- CANF 6.03
About SRM SRM Entertainment Inc.
SRM Entertainment Inc is a trusted toy and souvenir designer and developer, selling into theme parks and entertainment venues. It has developed, manufactured, and supplied the entertainment and amusement park industry with exclusive products that are often only available to consumers inside SRM's customer base venues such as Walt Disney Parks and Resorts, Universal Studios, SeaWorld, Six Flags, Great Wolf Lodge, Dollywood, and Merlin Entertainment. Its product category includes The Smurfs and Zoonicorns, Sammy Sloth, lilita Llama, kyle Koala, and Hanna Hedgehog.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).